Pacific Shuanglin Bio-pharmacy Co., Ltd. (000403.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 9.91

From 52W high−44.24%

Volume5.09M

Market capCNY 9.75B

P/E (TTM)23.3x

P/S (TTM)3.6x

Div yield—

Key dataSep 18, 2026

Open

CNY 9.91

From 52W high

−44.24%

Volume

5.09M

Market cap

CNY 9.75B

ValuationView details →

P/E (Fwd)

25.3x

EV/EBITDA

14.3x

P/E (TTM)

23.3x

RSI (14)

39.1

MomentumView details →

1D Return

−3.48%

YTD Return

−27.83%

ValuationView details →

P/E (Fwd)

25.3x

P/E (TTM)

23.3x

EV/EBITDA

14.3x

EV/Sales

3.7x

P/S (TTM)

3.6x

P/B (TTM)

1.2x

ProfitabilityView details →

Gross Margin

39.71%

Net Margin

13.58%

EBITDA Margin

25.89%

ROE (TTM)

4.35%

ROA (TTM)

3.76%

Asset Turnover

0.28x

GrowthView details →

Revenue YoY

+0.28%

EPS YoY

−47.14%

FCF YoY

—

Revenue CAGR 3Y

+3.06%

EPS CAGR 3Y

−18.19%

EBITDA YoY

—

MomentumView details →

1D Return

−3.48%

YTD Return

−27.83%

1Y Return

−42.15%

RSI (14)

39.1

vs 50D SMA

−4.06%

vs 200D SMA

−19.07%

Capital & dividendView details →

Debt/Equity

0.09x

Current Ratio

3.37x

Quick Ratio

1.67x

Div Yield

—

Div Rate

—

Div Growth 1Y

+0.02%

EarningsView details →

EPS (Actual)

CNY 0.07

EPS Surprise

−72.49%

Beats (12Q)

0/12

Next Q EPS Est

CNY 0.28

Avg Surprise (4Q)

−72.49%

Rev Surprise

0.00%

Financials snapshotView financials →

Revenue (TTM)

2.60B

Net Income (TTM)

353.15M

Op. CF (TTM)

−272.00M

Next earningsNov 2, 2026 →

Latest newsMore news →

Pailin Biologics reported its 2026 first-half results on August 23, with net profit attributable to shareholders down 64.25% year-on-year to 84.301 million yuan and revenue down 15.88% to 830 million yuan.28d ago

Pailin Biologics proposed a cash dividend of 1.5 yuan per 10 shares (tax included) for the first half of 2026.28d ago

Similar companies

聚飞光电300303.SZ 天润工业002283.SZ 钧崴电子301458.SZ 利安隆300596.SZ 天康生物002100.SZ 佐力药业300181.SZ Find similar companies →

Latest newsMore news →

Pailin Biologics reported its 2026 first-half results on August 23, with net profit attributable to shareholders down 64.25% year-on-year to 84.301 million yuan and revenue down 15.88% to 830 million yuan.28d ago Pailin Biologics proposed a cash dividend of 1.5 yuan per 10 shares (tax included) for the first half of 2026.28d ago